Skip to main content
. 2016 Feb 12;7(10):11708–11723. doi: 10.18632/oncotarget.7336

Figure 6. Lip-FLLL32 sensitizes pancreatic cancer to radiotherapy by reducing pancreatic CSCs.

Figure 6

(A) Tumorsphere formation assay of free FLLL32 (left) or liposomal FLLL32 (right) treated PANC-1cells at indicated doses. Spheres of each treatment were counted and compared to vehicle controls. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA. (B) Flow cytometry analysis of ALDH1+ population in PANC-1 cells treated with FLLL32 at indicated doses for 24 hours combining with or without 10 Gy radiation treatment. *P < 0.05, **P < 0.01, two-way ANOVA; a, P < 0.01, t-test, Radiation only vs no treatment. (C) Flow cytometry analysis of ALDH1+ population in xenograft tumor samples from mice treated with Lip only, radiation, liposomal FLLL32, or their combination for one week. (D) The relative mRNA expression of stem cell-associated genes in Lip-FLLL32 treated PANC-1 cells was analyzed using Human Stem Cell Primer Library and quantitative real-time reverse transcription PCR. Gene expression in Lip-FLLL32 treated cells was normalized to β-actin and β-2-microglobulin and set relative to that of Lip only treated PANC-1 cells.